Semifinalist Teams Selected in $10M ANA Avatar XPRIZE Competition
5.4.2021 18:00:00 EEST | Business Wire | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 38 teams from 16 countries are advancing to the semifinals round of the $10M ANA Avatar XPRIZE competition.
Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those interactions. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing.
“We are rapidly approaching an era where it will be possible for a doctor in New York to export their skillset virtually to respond to a natural disaster across the globe,” said Anousheh Ansari, CEO of XPRIZE. “The task at hand for these incredible semifinalist teams competing in the ANA Avatar XPRIZE is to break through physical limitations and expand the capacity of humankind itself through transformative robotic avatar technology.”
In February 2021, qualified teams completed their semifinalist selection submissions—the second round of technical submissions for evaluation by the judging panel. Each team submitted a comprehensive write-up detailing their avatar system's capabilities and their development plans, accompanied by a demonstration video showcasing their technology in action. The judges extensively reviewed the submissions and selected 38 semifinalists to advance out of the field of 77 qualified teams.
The ANA Avatar XPRIZE semifinalist teams are:
- 1to1Robotics, Hackensack, New Jersey, United States
- Aham, Bangalore, India
- Augnition, Helsinki, Finland
- AvaDynamics, Pittsburgh, Pennsylvania, United States
- Avatar Quest, San Jose, California, United States
- AVATRINA, Urbana, Illinois, United States
- BellContinuous, Arlington, Texas, United States
- Cyberselves, Sheffield, United Kingdom
- Dragon Tree Labs, Moscow, Russia
- ENZO AVATAR, Bucaramanga, Colombia
- Forged Droids, Tempe, Arizona, United States
- GITAI, Tokyo, Japan
- H2L, Tokyo, Japan
- Human Fusions, Cleveland, Ohio, United States
- i-Botics, Utrecht, Netherlands
- iCub, Genoa, Italy
- Inbiodroid, Irapuato, Mexico
- Janus, Tsukuba, Japan
- Junnichi Suko, Tokyo, Japan
- Kimaera Dynamics, Toronto, Canada
- Last Mile – small world project 2, Osaka, Japan
- Limitless, Lugano, Switzerland
- NimbRo, Bonn, Germany
- Pollen Robotics, Bordeaux, France
- proRobot, Vysoké Mýto, Czech Republic
- Rezilient, St. Louis, Missouri, United States
- Robot Guru (HoloSuit), Mysuru, India
- Robotics Services LLC, Providence, Rhode Island, United States
- Roboy, Munich, Germany
- Sant'Anna, Pisa, Italy
- SYNAPSE, Tokyo, Japan
- Team Northeastern, Boston, Massachusetts, United States
- Team SNU, Ulsan, South Korea
- Team UNIST, Seoul, South Korea
- Telexistence, Tokyo, Japan
- Touchlab, Edinburgh, United Kingdom
- Virtual Sapiens, Chennai, India
- X-Presence, Kobe, Japan
Additional details about all competing teams can be found here.
“The breakthroughs that will develop out of the ANA Avatar XPRIZE have the potential to entirely reimagine the human experience,” said David Locke, Executive Prize Director of ANA Avatar XPRIZE. "We’re thrilled to announce the semifinalist teams and are excited to put their technologies to the test, and experience their ability to transport our sense of presence, during semifinals testing this fall.”
"Now that the semifinalist teams have been chosen, we are one very important step closer to realizing our dream of revolutionizing human connection," said Mitsuo Tomita, Senior Vice President of Marketing at All Nippon Airways. "As a company whose mission it is to connect people, we are beyond excited to see the technology that will be developed by these 38 teams. We are eager to see the innovative ways in which the teams will light up our imaginations with visions of a future in which travel and human connection are limitless."
After the completion of semifinals testing in Fall 2021, up to 20 teams will equally split a Semifinals prize purse of $2M and move on to finals testing in Summer 2022. There, they will compete to win a share of the $8M finals prize purse.
The grand prize will be awarded in June 2022 after finals testing, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use case scenarios. The winning team will integrate multiple emerging technologies to develop a physical, nonautonomous avatar system with which an operator can see, hear, and interact within a remote environment in a manner that feels as if they are truly there.
The ANA Avatar Advisory Board has been integral in the competition since its launch in January 2019. The group consists of esteemed robotics experts, haptics inventors, psychology professors, top entertainment researchers, virtual world creators, computer vision dynamos and more. The full list of experts can be found below with additional information and bios available here.
For more information on the ANA Avatar XPRIZE, the semifinalist teams, and ANA, please visit avatar.xprize.org.
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.
ABOUT ANA
Founded more than 60 years ago in 1952 with just two helicopters, All Nippon Airways (ANA), has become the largest airline in Japan, serving 46 international destinations and 50 domestic destinations.
ANA HOLDINGS Inc. (ANAHD) was established in 2013 as the largest airline group holding company in Japan comprised of 78 companies including ANA and Peach Aviation Limited, the leading LCC in Japan. The 78 companies organized under the ANAHD umbrella operate in a diverse range of markets, including air transportation, travel services and trade, and retail embody ANAHD’s shared values of exceptional service, responsible corporate citizenship and investment in the communities where they operate.
ANA is a launch customer and the biggest operator of the Boeing 787 Dreamliner, making ANAHD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has Joint Venture agreements with United Airlines, Lufthansa Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines– giving it a truly global presence.
Supplementing its operations in commercial aviation, ANAHD has led the development of the innovative haptic robotics program, through its avatarin Inc. company, and its involvement in space with its partnership with JAXA, and other space related companies such as Astroscale and PD Aerospace.
The airline’s legacy of superior service has helped it earn SKYTRAX’s respected 5-Star rating every year since 2013, making ANA the only Japanese airline to win this prestigious designation and for eight consecutive years. ANA also has been recognized by Air Transport World as “Airline of the Year” three times (2007, 2013 and 2018); it is one of a select few airlines to win this prestigious award multiple times.
For more information, please refer to the following link:
https://www.ana.co.jp/group/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005239/en/
Contact information
Caden Kinard, XPRIZE
caden.kinard@xprize.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
